EarningsQ2 2026 Earnings Report
MX:GLBN Q2 2026 EPS Results
Actual EPS$13.84
Consensus EPS$11.95
Beat/MissBeat by +$1.89
One Year Ago EPS$10.74
MX:GLBN Q2 2026 Revenue Results
Actual Revenue$35.17B
Expected Revenue$34.91B
Beat/MissBeat by +$260.41M
YoY Revenue Growth+1.05%
Earnings Announcement Details
QuarterQ2 2026
Date08/06/2026
TimeBefore Open
Conference CallThursday, August 6, 2026
MX:GLBN Upcoming Earnings
Glanbia's next earnings date is estimated for March 3, 2027, based on past reporting schedules.
Q2 2026 Earnings Call Audio
MX:GLBN Q2 2026 Earnings Call
0:00 / 0:00
Q2 2026 Earnings Slide Deck
Q2 2026 Earnings Call Summary
Earnings Call Sentiment|Positive
The call presents a strongly positive operational and financial picture: significant top-line growth, a 30% increase in adjusted EPS, upgraded guidance, strong cash conversion, and clear progress on transformation and digital initiatives. However, material near-term headwinds remain — notably record whey protein costs, some early price elasticity, supply-chain related raw material inflation (H&N) and one-off transformation charges — which management is actively addressing through pricing, procurement and efficiency measures. On balance, the positive performance, upgraded guidance and effective capital returns outweigh the challenges, but monitoring of input cost dynamics and consumer elasticity remains key.Company Guidance
Strong Earnings Per Share Growth
Adjusted EPS of $0.8124 for H1, representing constant currency growth of 30% versus prior year and prompting an upgraded full-year EPS guidance to +17% to +20% CC.
Revenue and Volume Momentum
Group revenue of $2.1 billion, up 7% on a constant currency basis; like-for-like reported revenues up 10.7% with volumes up 8.2% and price up 2.5%.
Robust EBITDA and Margin Expansion
Pre-exceptional EBITDA of $275.4 million, up 14.1% CC, and group EBITDA margin of 13.2%, an expansion of 80 basis points versus prior year.
Outperformance Across Segments
Performance Nutrition like-for-like revenue +16.9% (volume +9.3%, price +7.6%); Health & Nutrition like-for-like revenue +12% (volume +14.3%); Dairy Nutrition like-for-like revenue +3.8% (volume +4.6%).
Dairy Nutrition and Health & Nutrition Profitability
Dairy Nutrition EBITDA $92.3 million in DN (up 28.2% YoY); Health & Nutrition EBITDA $67.9 million (up 9.5% CC) with DN and H&N driving margin expansion across the group.
Brand Leadership — Optimum Nutrition and Isopure
Optimum Nutrition (79% of PN revenue) delivered like-for-like revenue growth of 25.2% and US consumption up 23.5% in the 13 weeks to July 4; Isopure showing double-digit US consumption growth in FDMC and online and household penetration gains.
Strong Cash Generation and Capital Allocation
Operating cash flow of $507 million for the trailing 12 months with operating cash conversion of 95.1%; net debt ~$731 million, net debt/adjusted EBITDA 1.4x (expected ~1x at year-end); interim dividend increased 10% and EUR 100 million of share buybacks completed (≈4.9m shares at €20.49 average).
Transformation, Efficiency and Technology Progress
Group-wide transformation savings target increased from $60m to $70m annual by 2027, ~40% of savings expected by year-end; digital/IT operating model roll-out and focused AI deployments; ~$85m of ~$110m program charges incurred to date.
Upgraded Segment Guidance
Performance Nutrition revenue now guided to +12% to +14% LFL for the year; Health & Nutrition LFL revenue guided to +8% to +10%; Dairy Nutrition EBITDA guidance raised to $170m–$180m; J/V profit after tax now expected ~ $20m for the year.
MX:GLBN Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed